Want to see TVTX full AI Analyst Report?
Total Valuation
Travere Therapeutics has a market cap or net worth of $6.19B. The enterprise value is $5.44K.
Market Cap$6.19B
Enterprise Value$5.44K
Share Statistics
Travere Therapeutics has 94,261,086 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,261,086
Owned by Insiders1.58%
Owned by Institutions35.47%
Financial Efficiency
Travere Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -13.95%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-13.95%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee987.38K
Profits Per Employee-51.40K
Employee Count497
Asset Turnover0.81
Inventory Turnover1.76
Valuation Ratios
The current PE Ratio of Travere Therapeutics is ―. Travere Therapeutics’s PEG ratio is 0.79.
PE Ratio―
PS Ratio6.95
PB Ratio29.69
Price to Fair Value29.69
Price to FCF-167.32
Price to Operating Cash Flow65.77
PEG Ratio0.79
Income Statement
In the last 12 months, Travere Therapeutics had revenue of 490.73M and earned -25.55M in profits. Earnings per share was -0.56.
Revenue490.73M
Gross Profit480.39M
Operating Income-62.82M
Pretax Income-49.27M
Net Income-25.55M
EBITDA22.22M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was 92.70M and capital expenditures -41.18M, giving a free cash flow of 51.52M billion.
Operating Cash Flow92.70M
Free Cash Flow51.52M
Free Cash Flow per Share0.55
Dividends & Yields
Travere Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.73
52-Week Price Change278.53%
50-Day Moving Average58.22
200-Day Moving Average40.98
Relative Strength Index (RSI)65.25
Average Volume (3m)1.78M
Important Dates
Travere Therapeutics upcoming earnings date is Oct 22, 2026, After Close (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateOct 22, 2026
Ex-Dividend Date―
Financial Position
Travere Therapeutics as a current ratio of 2.74, with Debt / Equity ratio of 2515.72%
Current Ratio2.74
Quick Ratio2.70
Debt to Market Cap0.09
Net Debt to EBITDA10.61
Interest Coverage Ratio-5.85
Taxes
In the past 12 months, Travere Therapeutics has paid 988.00K in taxes.
Income Tax988.00K
Effective Tax Rate-0.02
Enterprise Valuation
Travere Therapeutics EV to EBITDA ratio is 164.03, with an EV/FCF ratio of -178.89.
EV to Sales7.43
EV to EBITDA164.03
EV to Free Cash Flow-178.89
EV to Operating Cash Flow96.46
Balance Sheet
Travere Therapeutics has $489.18M in cash and marketable securities with $616.90M in debt, giving a net cash position of -$127.73M billion.
Cash & Marketable Securities$489.18M
Total Debt$616.90M
Net Cash-$127.73M
Net Cash Per Share-$1.36
Tangible Book Value Per Share$0.02
Margins
Gross margin is 94.41%, with operating margin of -12.80%, and net profit margin of -5.21%.
Gross Margin94.41%
Operating Margin-12.80%
Pretax Margin-10.04%
Net Profit Margin-5.21%
EBITDA Margin4.53%
EBIT Margin-7.85%
Analyst Forecast
The average price target for Travere Therapeutics is $74.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$74.67
Price Target Upside30.17% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast77.12%
EPS Growth Forecast64.40%